Maynard K, Musk P, Daunter B, Khoo S K, Parsons P G
Aust J Exp Biol Med Sci. 1985 Jun;63 ( Pt 3):333-41. doi: 10.1038/icb.1985.39.
Lymphoblastoid cell lines (LCLs) were established from 83 patients with ovarian cancer by transformation of peripheral B lymphocytes with Epstein-Barr virus. Comparing the melphalan resistance of different groups of LCLs using the mean Do obtained from clonogenic survival assays, LCLs from melphalan-treated patients were significantly more resistant than LCLs from patients not treated with this drug. However, prior treatment of the patient with ionizing radiation was not associated with increased in vitro resistance of the LCL to this agent. In melphalan-treated patients where LCLs were established serially, the melphalan Do increased after further melphalan treatment in vivo and decreased when no further treatment was given. No correlation was found between age of donor and LCL resistance to any of the above agents. A group of 15 LCLs previously established from non-tumour donors was less resistant to melphalan than the LCLs from patients with ovarian cancer. In a group of 29 patients with advanced disease in whom the clinical response was known, LCL resistance to melphalan appeared to be associated with poor clinical response to cross-linking agents. These results suggest that B cell populations undergo long term, but not necessarily permanent, increases in resistance to melphalan.
通过用爱泼斯坦-巴尔病毒转化外周血B淋巴细胞，从83例卵巢癌患者中建立了淋巴母细胞样细胞系（LCLs）。使用克隆形成存活试验获得的平均Do比较不同组LCLs对美法仑的耐药性，接受美法仑治疗患者的LCLs比未接受该药物治疗患者的LCLs耐药性显著更高。然而，患者先前接受电离辐射与LCLs对该药物的体外耐药性增加无关。在连续建立LCLs的美法仑治疗患者中，体内进一步接受美法仑治疗后美法仑Do增加，未接受进一步治疗时则降低。未发现供体年龄与LCLs对上述任何药物的耐药性之间存在相关性。一组先前从非肿瘤供体建立的15个LCLs对美法仑的耐药性低于卵巢癌患者的LCLs。在一组29例已知临床反应的晚期疾病患者中，LCLs对美法仑的耐药性似乎与对交联剂的临床反应不佳有关。这些结果表明，B细胞群体对美法仑的耐药性会经历长期但不一定是永久性的增加。
